Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natal…
Butzkueven H; Kalincik T; Patti F; Slee M; Weinstock-Guttman B; Buzzard K; Skibina O; Alroughani R; Prat A; Girard M; Horakova D; Havrdova EK; Van der Walt A; Eichau S; Hyde R; Campbell N; Bodhinathan K; Spelman T; MSBase Investigators.
Ther Adv Neurol Disord
(Unknown)
Published: 2024
Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates wi…
Teschner VE; Fleck AK; Walter C; Schwarze AS; Eschborn M; Wirth T; Steinberg OV; Schulte-Mecklenbeck A; Lu IN; Herrera-Rivero M; Janoschka C; Lünemann JD; Schwab N; Meyer Zu Hörste G; Varghese J; Gross CC; Pul R; Kleinschnitz C; Mader S; Meinl E; Stoll M; Wiendl H; Klotz L.
Ther Adv Neurol Disord
(Unknown)
Published: 2023
Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes:…
Kassubek J; Stocchi F; Martinez EB; Pahwa R; Ondo W; Zhang Y; Bowling A; Pappert E; Isaacson S; Wu S; CTH-302 Study Investigators*.
Ther Adv Neurol Disord
(Unknown)
Published: 2023
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
Allen-Philbey K; De Trane S; MacDougall A; Adams A; Bianchi L; Campion T; Giovannoni G; Gnanapavan S; Holden DW; Marta M; Mathews J; Turner BP; Baker D; Schmierer K.
Ther Adv Neurol Disord
(Unknown)
Published: 2023
Structural connections of the centromedian nucleus of thalamus and their relevance for neuromodulation in generalized d…
Remore LG; Rifi Z; Nariai H; Eliashiv DS; Fallah A; Edmonds BD; Matsumoto JH; Salamon N; Tolossa M; Wei W; Locatelli M; Tsolaki EC; Bari AA.
Ther Adv Neurol Disord
(Unknown)
Published: 2023
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T.
Ther Adv Neurol Disord
(Unknown)
Published: 2023
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the op…
Coles AJ; Achiron A; Traboulsee A; Singer BA; Pozzilli C; Oreja-Guevara C; Giovannoni G; Comi G; Freedman MS; Ziemssen T; Shiota D; Rawlings AM; Wong AT; Chirieac M; Montalban X.
Ther Adv Neurol Disord
(Unknown)
Published: 2023
Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German …
Salmen A; Hoepner R; Fleischer V; Heldt M; Gisevius B; Motte J; Ruprecht K; Schneider R; Fisse AL; Grüter T; Lukas C; Berthele A; Giglhuber K; Flaskamp M; Mühlau M; Kirschke J; Bittner S; Groppa S; Lüssi F; Bayas A; Meuth S; Heesen C; Trebst C; Wildemann B; Then Bergh F; Antony G; Kümpfel T; Paul F; Nischwitz S; Tumani H; Zettl U; Hemmer B; Wiendl H; Zipp F; Gold R.
Ther Adv Neurol Disord
(Unknown)
Published: 2023